Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
Saved in:
| Title: | Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. |
|---|---|
| Authors: | Ferdinandus J; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany. Electronic address: justin.ferdinandus@uk-koeln.de., Schneider G; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany., Moccia A; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Hematology Clinic, Bellinzona, Switzerland., Greil R; IIIrd Medical Department, Paracelcus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Salzburg, Austria; Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Salzburg, Austria., Hertzberg M; Department of Haematology, Prince of Wales Hospital and UNSW, Sydney, NSW, Australia; Australasian Leukaemia & Lymphoma Group (ALLG), Melbourne, VIC, Australia., Schaub V; Department of Internal Medicine II, University of Tübingen, Tübingen, Germany., Hüttmann A; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany., Keil F; Department of Haematology, Hanusch Krankenhaus, Vienna, Austria., Dierlamm J; Department of Internal Medicine II, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Hänel M; Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany., Novak U; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, University Hospital Bern, Bern, Switzerland., Meissner J; Department of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany., Hellmuth JC; Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany., Mathas S; Department of Hematology and Oncology, Charité University of Medicine, Berlin, Germany., Zijlstra JM; Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, Netherlands., Fosså A; Department of Oncology, Oslo University Hospital, Oslo, Norway; Nordic Lymphoma Group., Viardot A; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Hertenstein B; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany., Martin S; Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany., Giri P; Department of Haematology and Bone Marrow Transplant, Royal Adelaide Hospital, Adelaide, SA, Australia., Kamper P; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Nordic Lymphoma Group., Molin D; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden; Nordic Lymphoma Group., Jablonski J; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany., Damaschin C; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany., Robertz AS; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany., Rosenbrock J; German Hodgkin Study Group (GHSG), Cologne, Germany; Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Fuchs M; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany., Borchmann P; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany., Behringer K; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2025 Aug; Vol. 26 (8), pp. 1081-1090. Date of Electronic Publication: 2025 Jul 10. |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial; Comparative Study |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
